Earnings summaries and quarterly performance for Invivyd.
Executive leadership at Invivyd.
Board of directors at Invivyd.
Research analysts who have asked questions during Invivyd earnings calls.
Patrick Trucchio
H.C. Wainwright & Co.
5 questions for IVVD
Also covers: ALT, ARWR, ATAI +13 more
Maxwell Skor
H.C. Wainwright & Co.
3 questions for IVVD
Also covers: ASND, AVIR, CRNX +4 more
Alexa Deemer
Cantor Fitzgerald
2 questions for IVVD
Also covers: SPRY, TRVI
Arabella
HC Wainwright
2 questions for IVVD
Jason Kolbert
D Boral Capital
2 questions for IVVD
Also covers: BCDA, CANF, HUMA +6 more
Jenna Li
Jefferies
2 questions for IVVD
Also covers: ADCT, RVMD
Michael Yee
Jefferies
2 questions for IVVD
Also covers: ALLO, AMGN, BEAM +14 more
Evan Wang
Guggenheim Securities
1 question for IVVD
Also covers: ARCT, BOLD, IVA +1 more
Kaiyue Yang
Jefferies
1 question for IVVD
Also covers: SDGR
Recent press releases and 8-K filings for IVVD.
Invivyd Advances Next-Generation COVID-19 Monoclonal Antibody VYD2311 to Pivotal Trial
IVVD
Product Launch
New Projects/Investments
- Invivyd is progressing VYD2311, a next-generation monoclonal antibody for COVID prevention, into a pivotal trial for a Biologics License Application (BLA), targeting an intramuscular injection for broader patient access.
- VYD2311 demonstrates 15- to 17-fold higher potency than PEMGARDA's predecessor, enabling a significantly lower dose (sub-300 mg) and an anticipated price in the hundreds per dose, aiming for 80%+ pharmaceutical-like margins.
- The pivotal trial is slated to commence by the end of 2025 or early Q1 2026, with a data package submission to the FDA projected for mid-2026, potentially leading to market entry within a year of submission.
- The company also announced an RSV candidate with an Investigational New Drug (IND) application planned for later in 2026.
3 days ago
Invivyd Provides Update on Next-Gen COVID Antibody 2311 and RSV Program
IVVD
New Projects/Investments
Guidance Update
Product Launch
- Invivyd is advancing its next-generation COVID-19 prevention antibody, 2311, into a pivotal trial for a Biologics License Application (BLA), with the first patient expected by Q1 2026 and a data package submission to the FDA targeted for mid-2026.
- 2311 is designed as an intramuscular injection with significantly higher potency (15- to 17-fold increase) compared to the current IV-administered PEMGARDA.
- The company anticipates a price point for 2311 in the hundreds of dollars per dose, a substantial reduction from PEMGARDA's approximately $6,500 gross price, while targeting 80%+ pharmaceutical-like margins.
- Invivyd also announced an RSV candidate with an Investigational New Drug (IND) application planned for late 2026.
3 days ago
Invivyd Provides Update on VYD2311 Pivotal Trial and Pipeline Developments
IVVD
Product Launch
New Projects/Investments
- Invivyd is advancing its next-generation COVID prevention asset, VYD2311, into a pivotal trial for a Biologics License Application (BLA), aiming for a fully licensed product. This product is designed as an intramuscular injection with 15- to 17-fold higher potency than PEMGARDA, and is expected to have a price point in the hundreds of dollars per dose, targeting 80%+ pharmaceutical-like margins.
- The pivotal trial for VYD2311 is set to begin by the end of 2025 or early Q1 2026, with a data package submission to the FDA anticipated around mid-2026.
- VYD2311 is expected to provide protection for three months with a single dose, given its half-life of 60 to 70 days.
- Invivyd also announced an RSV candidate with an Investigational New Drug (IND) submission targeted for later in 2026.
3 days ago
Invivyd Prices Public Offering of Common Stock and Warrants
IVVD
- Invivyd, Inc. priced an underwritten public offering of 44,000,000 shares of common stock at $2.50 per share and 6,000,000 pre-funded warrants at $2.4999 per pre-funded warrant.
- The offering is expected to generate approximately $125.0 million in gross proceeds, with approximately $117.2 million in net proceeds after deducting underwriting discounts and offering expenses.
- The net proceeds will be used for commercial preparedness for the potential launch of VYD2311, continued research and development for pipeline programs such as respiratory syncytial virus (RSV) and measles, advancement of the Spike Protein Elimination and Recovery (SPEAR) Study Group efforts, and for working capital and other general corporate purposes.
- The offering closed on November 19, 2025.
Nov 19, 2025, 10:23 PM
Invivyd Announces Pricing of Public Offering
IVVD
New Projects/Investments
- Invivyd, Inc. announced the pricing of an underwritten public offering on November 17, 2025, for 44,000,000 shares of its common stock at $2.50 per share and pre-funded warrants to purchase 6,000,000 shares at $2.4999 per pre-funded warrant.
- The offering is expected to generate approximately $125.0 million in gross proceeds and is anticipated to close on or about November 19, 2025.
- Invivyd intends to use the net proceeds for commercial preparedness for the potential launch of VYD2311, continued research and development for pipeline programs (such as RSV and measles), advancement of the SPEAR Study Group efforts, and for working capital and other general corporate purposes.
- The company also granted the underwriters an option to purchase up to an additional 7,500,000 shares of common stock for a period of 30 days.
Nov 18, 2025, 3:40 AM
Invivyd Reports Q3 2025 Financial Results and Commercial Progress
IVVD
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Invivyd reported Q3 2025 PEMGARDA net product revenue of $13.1 million, representing 41% growth over Q3 2024 and 11% growth over Q2 2025.
- The company's cash and cash equivalents totaled $85.0 million at the end of Q3 2025, which increased to over $100 million by October 2025 after a public offering and at-the-market (ATM) facility usage.
- Invivyd has established a commercial foundation for PEMGARDA, with 811 accounts having infusion experience and 76% reordering accounts, and plans to scale this infrastructure for its VYD2311 candidate.
- The company is strategically positioning VYD2311 as a potential blockbuster monoclonal antibody, aiming to provide a non-vaccine alternative for COVID protection with anticipated high efficacy and long duration.
Nov 6, 2025, 1:30 PM
Invivyd Reports Q3 2025 Results, Secures Funding, and Advances VYD2311 Program
IVVD
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
- Invivyd announced Q3 2025 financial results, with Pemgarda revenues growing 11% quarter-on-quarter and 41% year-over-year.
- The company received U.S. FDA feedback for its VYD2311 antibody, with pivotal clinical studies on track to initiate around year-end and deliver top-line data in mid-2026.
- Invivyd raised approximately $87 million in capital in Q3 2025 and shortly thereafter, making it well-capitalized through anticipated pivotal data for VYD2311 in mid-2026.
- The company stated it has no plans to actively sunset Pemgarda even after the potential approval of VYD2311.
Nov 6, 2025, 1:30 PM
Invivyd Reports Q3 2025 Results and VYD2311 Clinical Program Update
IVVD
Earnings
New Projects/Investments
Guidance Update
- Invivyd reported Q3 2025 PEMGARDA revenues that increased 11% quarter-on-quarter and 41% year-over-year.
- The company successfully raised approximately $87 million in capital during Q3 2025 and shortly thereafter, ensuring it is well-capitalized through anticipated pivotal data for VYD2311 in mid-2026.
- Following FDA feedback, Invivyd is on track to initiate pivotal clinical studies for its VYD2311 antibody around year-end, with top-line data expected in mid-2026.
- Invivyd is expanding its commercial organization in preparation for the VYD2311 launch, while continuing to grow its PEMGARDA commercial franchise.
Nov 6, 2025, 1:30 PM
Invivyd Announces Q3 2025 Financial Results and VYD2311 Clinical Progress
IVVD
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
- Invivyd reported strong Q3 2025 financial results, with Pemgarda revenues increasing 11% quarter-on-quarter and 41% year-over-year.
- The company successfully raised approximately $87 million in capital, securing funding through anticipated pivotal data for VYD2311 in mid-2026.
- The pivotal clinical program for VYD2311 is on track to initiate around year-end, with top-line data expected in mid-2026, targeting a potential blockbuster market.
- Invivyd is expanding its commercial organization in preparation for the VYD2311 launch and is also pursuing early-stage discovery programs in RSV and measles, with an update expected before year-end.
Nov 6, 2025, 1:30 PM
Invivyd Reports Q3 2025 Financial Results and VYD2311 Clinical Progress
IVVD
Earnings
Product Launch
New Projects/Investments
- Invivyd reported PEMGARDA net product revenue of $13.1 million for Q3 2025, marking 41% growth year-over-year and 11% growth quarter-over-quarter.
- The company's cash and cash equivalents stood at $85.0 million as of September 30, 2025, with October 2025 ending cash exceeding $100 million following a $57.5 million public offering in August 2025 and an additional $29.8 million from an at-the-market offering in October 2025.
- Invivyd announced U.S. IND clearance and FDA alignment for VYD2311, a vaccine-alternative antibody for COVID, with its REVOLUTION pivotal clinical program expected to commence around year-end 2025 and top-line data anticipated mid-2026.
- Net loss for Q3 2025 significantly decreased to $10.5 million, compared to $60.7 million in Q3 2024, resulting in a basic and diluted net loss per share of $0.06.
Nov 6, 2025, 12:10 PM
Quarterly earnings call transcripts for Invivyd.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more